Guide

OAI, VAI and NAI: FDA inspection classifications, explained

Official Action Indicated (OAI) is the most serious inspection classification FDA assigns. Every FDA inspection is classified after it closes as NAI (No Action Indicated), VAI (Voluntary Action Indicated) or OAI; the classification is FDA’s summary judgment of what the inspection found and whether the agency intends to act on it.

The three classifications

NAI No Action Indicated. No objectionable conditions or practices were found, or those found do not justify further action. In some cases, minor issues may have been pointed out but remediated to the satisfaction of the FDA prior to the close of the inspection. The most common classification for clinical investigator inspections.

VAI Voluntary Action Indicated. Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action; correction is left to the clinical investigator. VAI is a wide band: it covers a documentation gap and it covers a near-miss serious problem, which is why the findings behind a VAI matter more than the label.

OAI Official Action Indicated. Objectionable conditions were found that FDA considers significant enough that correction cannot be left to the clinical investigator and regulatory or administrative action is indicated. Often it leads eventually to a warning letter. For a clinical investigator, OAI is also the doorway to disqualification proceedings when FDA believes the violations were repeated or deliberate.

Who assigns the classification, and when

The inspector does not classify the inspection. The inspector writes an establishment inspection report and, where warranted, issues a Form FDA 483 at the close of the visit. The reviewing center — for drug and biologic trials, CDER or CBER — evaluates the report, the 483 and any response the clinical investigator sent, and assigns the final classification. That review takes time: an inspection is classified weeks to months after it closes, and a classification can be revised after the investigator’s response is considered.

A 483 is not a classification. A Form FDA 483 lists what the inspector observed; it is issued on site, before any review. The classification is FDA’s decision about those observations, made afterward. An inspection can end with a 483 and still be classified NAI; an OAI inspection nearly always had one.

How often OAI happens

Rarely, as a share of inspections. In the drug and biologic clinical-research inspection record Clinical Precedent holds, roughly one inspection in thirty is classified OAI, about a third are VAI, and the rest NAI. The proportion has moved over time; see FDA clinical investigator inspections by year and classification for the counts.

What follows an OAI

For a clinical investigator, the usual next steps are one or more of:

A warning letter. FDA’s advisory letter setting out the violations and requesting a written response, normally within 15 working days. What it means for a sponsor: warning letters to clinical investigators.

An untitled letter or an informal conference — less formal ways FDA communicates that the findings need correcting.

Disqualification proceedings. Where FDA believes the clinical investigator repeatedly or deliberately violated the regulations or submitted false information, it may issue a NIDPOE letter, followed if unresolved by a NOOH letter. This is rare even among OAI inspections.

Scrutiny of the data. FDA may examine the data the clinical investigator contributed to any pending application, and may decide not to rely on some or all of it — which is where an investigator’s OAI becomes the sponsor’s problem.

What the classifications mean when you are selecting a site

An OAI on a candidate clinical investigator’s record is a read-the-findings situation, not a checkbox: what was cited, how long ago, whether it escalated, and whether the site’s responses and corrective action plans addressed it. A VAI is the classification where the findings matter most, because the band is so wide. And a history of NAI inspections is a positive fact worth recording, because it is a different answer from “never inspected.” How to weigh all of it before the Form FDA 1572 is signed: clinical investigator vetting and clinical investigator selection.

Questions this page answers

What does OAI mean in an FDA inspection?

OAI stands for Official Action Indicated. It is the most serious inspection classification FDA assigns, meaning the inspection found objectionable conditions significant enough that correction cannot be left to the clinical investigator and FDA considers regulatory or administrative action indicated. Often it leads eventually to a warning letter.

What is the difference between VAI and OAI?

Both mean the inspection found objectionable conditions. VAI (Voluntary Action Indicated) means FDA is leaving correction to the clinical investigator and does not intend regulatory action; OAI means correction cannot be left to the clinical investigator and FDA considers regulatory or administrative action indicated. The findings behind a VAI can range from minor to serious, so the classification alone says less than the findings do.

Is a Form FDA 483 the same as an OAI?

No. A Form FDA 483 is the list of observations the inspector hands over at the close of the inspection, before any review. The classification — NAI, VAI or OAI — is assigned afterward by the reviewing center once it has evaluated the report, the 483 and the clinical investigator’s response. An inspection can have a 483 and still be classified NAI.

Does FDA tell the sponsor when a clinical investigator inspection is classified OAI?

FDA sends inspection findings to the clinical investigator, not typically to the sponsor. The sponsor is formally notified if the investigator is later disqualified. In between, learning of an OAI depends on the investigator telling the sponsor, or on the sponsor following up.

How long after an inspection is it classified?

Typically weeks to months. The reviewing center has to evaluate the inspection report and any response before it classifies. The newest inspections in any record can therefore be that old when they first appear.

Check a name now, free. Screen a clinical investigator against FDA’s disqualification proceedings and debarment list. No account needed.

Run a free status check

Want the inspection record behind it? Inspections, findings and warning letters, benchmarked. Subscriptions start at $249 a month; access is immediate.

See a sample report See plans

About this guide. It is educational, and it is not regulatory or legal advice. The authorities are the Code of Federal Regulations, FDA’s guidance and ICH E6; where this guide and those sources differ, the sources govern.